Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T03:45:54.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.9%
    Check dated 2025-06-19T19:28:03.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has updated its date-related content, adding new dates in June and September 2025 while removing older dates from March 2025.
    Difference
    0.7%
    Check dated 2025-06-12T15:28:46.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:07:37.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T05:54:15.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The page has removed references to a trial involving Ibrutinib and Nivolumab for treating patients with relapsed or refractory classical Hodgkin lymphoma, which were also added back in the same form.
    Difference
    0.2%
    Check dated 2025-05-22T02:24:40.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.